Free Trial

Grace Therapeutics (GRCE) Stock Price, News & Analysis

Grace Therapeutics logo
$2.90 +0.02 (+0.69%)
As of 03:45 PM Eastern

About Grace Therapeutics Stock (NASDAQ:GRCE)

Key Stats

Today's Range
$2.82
$2.98
50-Day Range
$1.80
$3.04
52-Week Range
$1.75
$4.97
Volume
19,040 shs
Average Volume
57,082 shs
Market Capitalization
$29.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Grace Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

GRCE MarketRank™: 

Grace Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 458th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Grace Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Grace Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Grace Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Grace Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.75) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Grace Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Grace Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Grace Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Grace Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for GRCE.
  • Dividend Yield

    Grace Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Grace Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for GRCE.
  • News Sentiment

    Grace Therapeutics has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Grace Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for GRCE on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Grace Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.51% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 6.08% of the stock of Grace Therapeutics is held by institutions.

  • Read more about Grace Therapeutics' insider trading history.
Receive GRCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grace Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GRCE Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
GRCE: STRIVE-ON Results Reported
See More Headlines

GRCE Stock Analysis - Frequently Asked Questions

Grace Therapeutics' stock was trading at $3.74 at the beginning of 2025. Since then, GRCE shares have decreased by 22.5% and is now trading at $2.90.
View the best growth stocks for 2025 here
.

Grace Therapeutics, Inc. (NASDAQ:GRCE) posted its quarterly earnings results on Thursday, February, 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01.

Top institutional investors of Grace Therapeutics include Nantahala Capital Management LLC (11.62%), ADAR1 Capital Management LLC (3.39%) and Stonepine Capital Management LLC (2.90%).

Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
2/13/2025
Today
5/29/2025
Next Earnings (Estimated)
6/20/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRCE
Previous Symbol
NASDAQ:GRCE
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+313.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.14 per share
Price / Book
0.56

Miscellaneous

Free Float
8,770,000
Market Cap
$29.41 million
Optionable
N/A
Beta
0.89
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:GRCE) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners